Curated News
By: NewsRamp Editorial Staff
March 25, 2026
GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial
TLDR
- GeoVax's GEO-MVA vaccine completion of release testing positions the company to capture market share by addressing the global MVA vaccine supply gap through an expedited regulatory pathway.
- GeoVax completed clinical product release testing for its GEO-MVA vaccine, enabling an immune bridging study per EMA guidance to demonstrate comparability to an approved MVA vaccine.
- GeoVax's GEO-MVA vaccine development expands global vaccine supply for mpox and smallpox, enhancing preparedness for outbreaks and biodefense to protect public health worldwide.
- GeoVax's GEO-MVA vaccine uses Modified Vaccinia Ankara technology to target both mpox and smallpox, advancing through an expedited regulatory pathway with a pivotal Phase 3 trial planned.
Impact - Why it Matters
This development matters because it addresses a critical vulnerability in global health security. Mpox outbreaks in recent years have exposed gaps in vaccine supply and preparedness, while smallpox remains a bioterrorism concern. Currently, the world relies on a single manufacturer for MVA-based vaccines, creating a dangerous lack of redundancy. GeoVax's GEO-MVA vaccine could diversify supply chains, enhance national stockpiles, and improve rapid response capabilities for future outbreaks. For individuals, this means better protection against emerging infectious diseases and reduced risk in an interconnected world. For public health systems, it offers a more resilient defense infrastructure, potentially saving lives and reducing economic disruption during health crises.
Summary
GeoVax Labs, Inc., a clinical-stage biotechnology company, has achieved a significant milestone in its GEO-MVA vaccine program by completing clinical product release testing, positioning the company to advance toward a pivotal Phase 3 trial. The GEO-MVA vaccine, designed to protect against mpox and smallpox, is now scheduled for final release in early April, which will provide sufficient clinical material for an immune bridging study aligned with European Medicines Agency (EMA) guidance. This study, set to begin in the second half of 2026, aims to demonstrate comparability to an approved MVA vaccine through immunological endpoints, potentially leading to regulatory Marketing Authorization under an expedited pathway.
Key players in this development include David Dodd, Chairman and CEO of GeoVax, who emphasized that this progress marks a "pivotal inflection point" toward potential approval and commercialization. The company is also engaging in outreach discussions with global health stakeholders, including organizations involved in national stockpiles, military preparedness, and international outbreak response, to prepare for rapid distribution upon regulatory clearance. These efforts highlight the growing recognition of the need to expand global supply of MVA-based vaccines, especially given recent mpox outbreaks and evolving epidemiological patterns that underscore the importance of sustained preparedness.
The GEO-MVA program addresses a critical global supply gap, as current MVA vaccine production is concentrated with a single manufacturer, limiting redundancy for a platform essential against both mpox and smallpox. GeoVax's vaccine could serve as an additional source, supporting national stockpile programs, global outbreak response efforts, and military biodefense initiatives. For more information, visit www.geovax.com, where the company details its broader pipeline, including oncology and COVID-19 vaccine candidates. This news, distributed via NEWMEDIAWIRE, reflects GeoVax's commitment to advancing high-consequence infectious disease solutions, with forward-looking statements cautioning about potential risks in clinical trials, regulatory approvals, and competitive developments.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial
